Metformin Use May Not Improve Survival in Pancreatic Cancer Patients

Roongruedee Chaiteerakij, M.D., Ph.D.

PHILADELPHIA -- Use of the diabetes drug Metformin by patients with pancreatic ductal adenocarcinoma may not improve survival according to the results of a study performed at Mayo Clinic and presented today at the AACR Annual Meeting 2015, in Philadelphia by Roongruedee Chaiteerakij, M.D., Ph.D., of Mayo Clinic.

Read the press release from the American Association for Cancer Research.

MEDIA CONTACT: Joe Dangor, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu